Role of Lipistat in protection against isoproterenol induced myocardial necrosis in rats: a biochemical and histopathological study.
A test drug (Lipistat) comprising of equal-proportions of extracts of Terminalia arjuna, Inula racemosa Hook, latex of Commiphora mukul, in three different doses (225 mg/kg; 350 mg/kg; 450 mg/kg) were administered orally daily for 6 days a week for 60 days in rats. Thereafter, the rats were subjected to isoproterenol (ISO) induced (85 mg/kg, s.c. for 2 days) myocardial necrosis. Gross and microscopic examinations (histopathology) were done along with estimations of myocardial tissue high energy phosphates (HEP) stores and lactate content. Gross examination showed significant (P < 0.05) cardioprotection in Lipistat treated animals. On microscopic examination no statistically significant reduction in myocardial damage by 350 and 450 mg/kg of Lipistat were observed although loss of myocardial HEP stores and accumulation of lactate were significantly prevented. The results of the present study suggest the potential usefulness of Lipistat in the prevention of ischemic heart disease.
Seth
S D
SD
Department of Pharmacology, All India Institute of Medical Sciences, New Delhi.
Maulik
M
M
Katiyar
C K
CK
Maulik
S K
SK
D000255:Adenosine Triphosphate / Q000378:metabolism; D000318:Adrenergic beta-Agonists; D000818:Animals; D009202:Cardiomyopathies / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D005218:Fat Necrosis / Q000473:pathology; D005260:Female; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007545:Isoproterenol; D019344:Lactic Acid / Q000378:metabolism; D008297:Male; D009206:Myocardium / Q000473:pathology; D009210:Myofibrils / Q000473:pathology; D010725:Phosphocreatine / Q000378:metabolism; D008517:Phytotherapy; D051381:Rats; D017208:Rats, Wistar
D000318:Adrenergic beta-Agonists; D000960:Hypolipidemic Agents; D010725:Phosphocreatine; D019344:Lactic Acid; D000255:Adenosine Triphosphate; D007545:Isoproterenol